Chimeric Livers: Interspecies Blastocyst Complementation and Xenotransplantation for End-Stage Liver Disease.
Madelyn J BlakeClifford J SteerPublished in: Hepatic medicine : evidence and research (2024)
Orthotopic liver transplantation (OLT) currently serves as the sole definitive treatment for thousands of patients suffering from end-stage liver disease; and the existing supply of donor livers for OLT is drastically outpaced by the increasing demand. To alleviate this significant gap in treatment, several experimental approaches have been devised with the aim of either offering interim support to patients waiting on the transplant list or bioengineering complete livers for OLT by infusing them with fresh hepatic cells. Recently, interspecies blastocyst complementation has emerged as a promising method for generating complete organs in utero over a short timeframe. When coupled with gene editing technology, it has brought about a potentially revolutionary transformation in regenerative medicine. Blastocyst complementation harbors notable potential for generating complete human livers in large animals, which could be used for xenotransplantation in humans, addressing the scarcity of livers for OLT. Nevertheless, substantial experimental and ethical challenges still need to be overcome to produce human livers in larger domestic animals like pigs. This review compiles the current understanding of interspecies blastocyst complementation and outlines future possibilities for liver xenotransplantation in humans.
Keyphrases
- end stage renal disease
- newly diagnosed
- ejection fraction
- endothelial cells
- chronic kidney disease
- peritoneal dialysis
- stem cells
- squamous cell carcinoma
- radiation therapy
- induced apoptosis
- risk assessment
- cell therapy
- combination therapy
- induced pluripotent stem cells
- current status
- patient reported
- pi k akt
- endoplasmic reticulum stress